Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates.
Saved in:
| Title: | Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. |
|---|---|
| Authors: | Kalluri VS; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vlebleu@mdanderson.org.; Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA. vlebleu@mdanderson.org., Smaglo BG; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahadevan KK; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kirtley ML; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McAndrews KM; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mendt M; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang S; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maldonado AS; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sugimoto H; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Salvatierra ME; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Solis Soto LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Finch R; Department of Comparative Medicine, The University of Texas MD Anderson Cancer Center, Bastrop, TX, USA., Gagea M; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fluty AC; Verna Marrs and McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA., Ludtke SJ; Verna Marrs and McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA., Jack Lee J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain AK; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Varadhachary G; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shroff RT; Division of Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA., Maitra A; Department of Pathology and Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shpall E; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pant S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kalluri R; Department of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Bioengineering, Rice University, Houston, TX, USA.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.; Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA. |
| Source: | Nature communications [Nat Commun] 2025 Sep 30; Vol. 16 (1), pp. 8696. Date of Electronic Publication: 2025 Sep 30. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
